Are you getting the maximum royalty rate out of your pharma deal?
This article was originally published in Scrip
Executive Summary
Medtrack has published a new analysis of the average royalty rates in pharmaceutical deals signed in the past five years. Those deals involving products that were pending approval received average royalty rates of an astonishing 21%, while marketed products received a more moderate 12%.